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Cancer patient heterogeneities challenge disease management despite advances
in targeted therapies. Patient sub-populations are irresponsive to certain treat-
ments with unknown reason or differ in sensitivity, while mutations can cause
resistance and patient relapse. Several consortia of large-scale pharmacogenomic
screens against comprehensive panels of human cancer cell lines have therefore
been established. Although these resources provide novel genetic biomarkers of
cancer drug response, the predictive accuracy has still been lower than desired. It
is hypothesised that many drugs act upon their endogenous targets by hitch-hiking
on membrane channels. About 10% of the human genome encodes for transport-
related functions, a functional link between transporters and disease relevance
are yet largely unknown. This thesis therefore focuses on the roles of membrane
transporters in cellular drug response. Solute Carriers (SLCs), which represent
the second-largest family of membrane proteins in the human genome and the
largest class of transporters, are the central focus of this study. For systematic
identification, the analyses also include more well-known transporter family of
ATP-binding cassettes (ABC), which have a widely accepted role in mediating
drug resistance. The landscape of expression for both transporter families in cancer
tissues were analysed. Matrix factorisation based methods were also employed
in integrating multiple genetic data to observe tissue specificity patterns. It was
found that differential expression of several transporters are likely to link with
tumorigenesis. Moreover, functions of transporters in drug influx and eﬄux were
also computationally hypothesised. Several statistical methods were used and
compared, with a list of most potential candidates suggested for experimental
validation. The interaction between two transporters were also identified using
linear model with interaction terms. Both computational and biological challenges
and limitations of the project are discussed.
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Operators and abbreviations
Operators
tr(X) trace of a matrix X, i.e. sum of its diagonal elements
||Z||p `p norm of a vector Z
X′ Transpose of a matrix X∑
i sum over index i
A ·B dot product of vectors A and B
Abbreviations
ABC ATP-binding cassette membrane transporter superfamily
ANOVA Analysis of variance
AOC The scaled area over drug response curve (AOC ∈ [0, 1])
CCLE The Cancer Cell Line Encyclopedia
CFE Cancer functional events
EN Elastic Net regularisation
IC50 The concentration of an inhibitor where the response
(or binding) is reduced by half
GDSC The Genomics of Drug Sensitivity in Cancer project
SLC Solute carrier membrane transporter superfamily
TCGA The Cancer Genome Atlas
1 Introduction
Drug discovery is a costly process. The advancement of genome sequencing technology
has allowed scientists to detect the genetic causality of several diseases and this
has been an important process for identifying putative drug targets and discovery.
However, the average number of FDA approved drugs per year has fallen since 1990s
[1] despite human genetic information was more well understood. It has also been
estimated that the cost for pharmaceutical R&Ds will be doubled every 9 years
[2]. One of the reasons that the vast majority of investigational drugs failed during
clinical trial is that they demonstrated lower efficacy than expected while another
reason is insufficient safety as drugs may develop toxic side effects during the trials
[3]. Both of these issues can be hypothesised to be associated with functional roles
of membrane transporters in cellular drug disposition.
The success of drug disposition can generally be determined by four criteria:
absorption, distribution, metabolism, and excretion (ADME). Absorption refers
to the uptake of the drug in the body, normally through oral route. Distribution
describes specific tissues or organ where the drug appears to accumulate after
absorption. Metabolism refers to the effect of the drug that induces chemical changes
via enzyme catalysis, and the drug finally will be eliminated usually by the kidney or
liver as urine or faeces. Several steps in ADME criteria are associated with cellular
influx and eﬄux of drugs via membrane transporters. It is therefore important to
understand mechanisms of drugs entering a cell through membrane transporters, yet
this have mostly been understudied.
In this thesis, the main focus is therefore on the systematic elucidation of the
role of the two largest superfamilies of transporters, solute carriers (SLC) and ATP-
binding cassettes (ABC) transporters as determinants of cellular response to cancer
drugs. The two superfamilies have been evidenced to play more significant roles in
cellular drug uptake than other transporters or membrane channels and hence are
the central focus to this study. Overview of other transporters are however briefly
discussed in Chapter 2.
In Chapter 2, previous studies related to transporters are discussed. The endoge-
nous functions of SLC and ABC transporters have been linked to tumorigenesis,
which can be a result of insufficient or excessive intake of metabolites that facilitate
cell growth [4]. The discovery of high association of particular transporters in drug
sensitivity are also discussed here. Transporters such as ABCB1 is known as mul-
tidrug resistance transporter (MDR) due to its ability to utilise ATP hydrolysis to
actively pump several small molecules outside the cell [5]. On the contrary, SLC
transporters are more regarded as influx transporters [6]. They transport small
molecules including drugs that structurally resemble the natural metabolites of the
transporter (‘metabolite-likeness’ [7]). However, SLCs are currently regarded as the
most neglected transporter family in human [8].
Large-scale pharmacogenomic screening in cell lines has been a valuable database
for discovering novel drug targets. Drug screening consortia such as the Genomics of
Drug Sensitivity in Cancer (GDSC) Project [9] provide valuable data in systematic
identification of genetic effects in drug sensitivity. The main pipelines from GDSC
2consortium and the consistency of the data across multiple consortia [10] were also
discussed in Chapter 2.
Cellular transporters and their association with cancer drug mode of action have
not been characterised systematically [8], and this study therefore aims to address
this challenge. Genomic information across 1001 cell lines with drug sensitivity data
across 265 drugs were obtained from GDSC consortium, and several methods were
used to (1) identify the tissue characteristic expression specificity of all SLC and
ABC transporters using the moderated (Bayesian) t-test [11], (2) investigate the
transporter similarity of different cancer tissues, using matrix factorisation method
iCluster [12, 13] to integrate multiple genomic profiles, (3) detect the association
of transport gene expression level to drug sensitivity using multiple methods i.e.
correlation test, ANOVA, and linear model with regularisation, and (4) identify the
dependency for drug intake between two transporters using group-lasso based linear
model [14]. The methods and research materials are provided in Chapter 3.
Chapter 4 provides results from the analyses mentioned above. In the landscape
analysis, transporters that are over-expressed or under-expressed in particular tissues
were identified, and the strongest associations are linked to literature evidence for
cancer progression. In drug association analysis, several known and novel associations
were captured by different methods tested. The computational and biological limita-
tions and challenges of these results are discussed. Furthermore, it is promising to
investigate whether there are particular pairs of transporters that function together
in drug intake and uptake. Linear model with regularisation with interaction terms
of the features were included and a number of interactions were captured.
The combination of association results were discussed in Chapter 5 in order to
serve as rationale for candidate selection and prioritisation for experimental validation
of the top hits. A number of suggestions for improvements and the possible future
directions of the project were also included in this chapter, with limitations and
drawbacks of the methods used in the analyses also being discussed.
32 Background
2.1 Membrane Transporters
Membrane transporters serve as gateways for the exchange of endogenous and
exogenous substances between different transmembrane compartments to control the
cellular homoeostasis. While some molecules can diffuse through cell membranes,
many of them are lipid insoluble and require a transporter to enter the cell [7]. The
expression patterns of transporters are greatly varied, many of them are expressed
throughout multiple tissues, especially in epithelial tissues such as liver, kidney,
and intestine, and those with barrier functions [15]. Transporters can be found in
plasma membrane, and for eukaryotic cells, other membrane-bound organelles such as
mitochondria and vesicles. Transporters can be classified into solute carriers (SLC),
ion and water channels, and ATP-driven transporters or pumps. Two of the largest
classes of transporter families are solute carriers (SLC) and ATP-binding cassette
containing transporters (ABC) have been found to play critical roles in transporting
drugs inside the cells besides their major roles in transporting small molecules such
as nutrients and metabolites [5] [15]. Strong association between drug efficacies
and the abundance of particular transporters have been reported, leading to more
attention towards these two superfamilies. However, most studies of transporters
were performed in a small-scale experiment, particularly focusing on a number of
transporters to some drugs. Little evidence of studies focusing on those transporters
in genome-wide level, i.e. how the transporter of interest perform compared to other
transporters, and whether there are more complex factors associated drug uptake.
This holistic view of analysis will be referred to as systematic studies.
Other membrane transporters and channels that mediate specific substrates
include water channels (aquaporin) and ion channels. There are fewer evidences
about these channels in mediating drug uptake, which may be explained by the
structural dissimilarity of drugs and the substrates of these channels (water and
ions). The overview of membrane transporters and their localisations are displayed
in Figure 1.
2.1.1 Solute Carriers (SLC)
Health implications
Solute carriers (SLC) is the largest membrane transporter superfamily, consisting
of over 400 genes in the human genome [8]. It is the second largest family of
membrane-coded genes in the human genome. SLC superfamily transporters have
major roles in uptake of small molecules inside the cell. Different transporters are
specific to certain molecules (substrate), resulting in various specificity range to
drugs. For instance, transporters with broad range of substrate specificity such as
organic anion transporter 1 (OAT1 or SLC22A6), which naturally associate with
the transport of various substrates, have consequently been associated to several
drugs. Unfortunately, SLC transporters with narrower range of substrate specificities
(those that naturally carry only fewer substrates) have received very little attention
4Figure 1: Left: Figure from Hediger et al. [16] showing types of membrane transporters
in human. The upper rectangle shows the superfamily of solute carrier (SLC series)
which can be localised in the plasma membrane or other organelles. The lower
rectangle shows other types of transporters including water channel, ion channels
and pumps. Pumps require energy from ATP hydrolysis in eﬄux of molecules from
intracellular space (lower concentration) to the extracellular environment (higher
concentration of substances).
Right: the publication asymmetry from [8]. SLC is a relatively large family compared
to other protein families, yet received little attention compared to other protein
families, according to the number of publications.
from the community [17]. However, these transporters can be highly associated
to particular drugs. The impact of those narrow substrate SLC transporters to
health has been indicated through knockout studies of particular transporters as
well as the phenotypes observed for patients with Mendelian diseases. Lin et al. [17]
have recently reviewed the impact of SLC transporters in monogenic disorders and
also more common disorders through genome-wide association studies (GWASs).
Information regarding SLC transporters substrate specificity have been collected
in www.bioparadigms.org. The database contains brief information about their
natural substrates as well as associated diseases. The information regarding drug
specificity, as previously mentioned, is barely known for the majority of transporters.
The endogenous functions of SLC transporters at a physiological level have been
highlighted [15], suggesting that the SLC and ABC superfamilies are likely to be a
part of the complex signalling processes known as remote communication system
in different scales. Nigam [15] explained it as the effect of transporters, especially
those in tissues that are interfacing body fluids, in controlling the exchanges of small
molecules involved in signalling pathways or in key steps of metabolism. This sensing
mechanism could be found at intra- and intercellular level, and are believed to be
present at tissue and organ level. This findings has led to higher complexity level of
indirect effects of transporter functions in diseases.
5Despite the importance of SLC transporters, they are the most neglected group
of genes in the human genome. César-Razquin et al. [8] calculated the ‘publication
asymmetry’ (Figure 1), which is measured by the skewness of the distribution of
the number of publications for all genes in a group. There is only a small proportion
of genes in the SLC superfamily that have been well studied with significantly high
number of publications (SLC6A4, serotonin transporter gene has been mentioned
in over 1,500 publications) while the majority of genes in the superfamily have not
yet been caught sufficient attention in the scientific community (226 SLC genes
have been mentioned in less than 15 publications). This is therefore a challenge for
systematic characterisation of SLC families, especially those transporter with lesser
known functions.
SLCs as drug transporters
As briefly discussed in Chapter 1 that a drug can be effective when it successfully
enters the cell and reaches its target while being disposed in the right amount. It
is therefore important to understand mechanisms of drugs entering a cell through
membrane transporters, yet this have mostly been understudied.
Besides the endogenous roles for the influx and eﬄux of metabolites and nutrients,
many SLC transporters appear to be ‘multi-specific drug transporters’. Kell [7]
and Dobson & Kell [6] argued that drugs might be able to pass through particular
transporters because of their structural similarity to the natural endogenous substrates
of the transporters (‘hitchhiking’). For example, the knockout of SLC35F2 transporter
significantly reduced the efficacy of anticancer drug YM155 [18] [19]. The term
‘metabolite-likeness’ [20] has been introduced to indicate the importance of the
similarity of drug molecules to endogenous substrates.
Many drugs are highly associated with a particular transporter. Additional
to transporter SLC35F2 and drug YM155 mentioned above, several other SLC
transporters, especially the genes in SLC6 and SLC22 families, have already been
targeted by FDA-approved drugs [8]. One major clinical concern regarding drug
specificity in this case are potential drug-drug interactions. At transporter level,
drugs might compete against each other to transit through the transporter in order
to enter the cell. This may lead to drug accumulation in serum or tissues and might
induce toxicity. On the contrary, a number of SLC transporters have overlapping
substrate specificity which leads to common associations to the same drug. However,
due to differential expression of these transporters in different tissues, the specificities
in tissue level are varied. Being able to characterise the specificity of theses drugs
can therefore be valuable in further identification of drug dispositions (how drug
successfully reach the endogenous targets) and estimating drug efficacy and optimal
dosage.
2.1.2 ATP-binding cassettes (ABC) transporters
The ATP-binding cassette (ABC) superfamily of transporters comprises about 50
transporter coding genes, which makes it a much smaller superfamily compared to
SLCs. They however have important functions related to drug transport [5] [21].
6The structure of ABC contains subunits that allow them to utilise energy from
ATP hydrolysis to facilitate the transport of various substrates. The roles of ABC
transporters have been identified to be primarily associated with the uptake or export
of endogenous molecules including several drugs, resulting in drug resistance. A
number of ABC transporters have been well characterised, such as ABCB1. It is
an important transporter capable of pumping broad range of foreign substrates out
of cell and have been found to mediate drug resistance. ABCB1 is also known as
multi-drug resistance 1 (MDR1) protein. The other well known ABC transporters
that found to be associated with drug resistance are the ABCC subfamily (multidrug
resistance associated proteins; MRPs) and ABCG2 [5].
Furthermore, similar to the hypothesis Nigam [15] proposed regarding the endoge-
nous roles of SLC transporters, Fletcher et al. [21] also pointed attention to more
fundamental roles of ABC transporters in tumour biology, especially their functions in
coordinating signalling pathways during tumorigenesis. Targeted functional analyses
such as gene knock-out or case-control studies are required to unveil whether ABC
transporter expression is associated with cancer progression. Further concerns for
future therapies towards ABC transporters, however, are the fact that many of them
are functionally redundant. Therefore, combinations of different inhibitors (drugs)
will be required to block the transport function more effectively compared to single
inhibitor.
2.2 High-throughput small molecule in-vitro screening
Understanding molecular mechanisms of cancer and discovery of effective therapeutics
remains a challenging task and it has been progressing relatively slowly[3]. As a
result of recent biotechnological advancement and availability of high quality genomic
data, exploiting the approaches of large-scale data analysis has become possible
to overcome the hurdle. Performing robust analyses on pharmacogenomic data at
preclinical level could potentially shed lights on the discovery of novel drug targets
and consequently reduce the cost and time spent on clinical trials. A number of
consortia have been established to specifically study the association of genetic and
pharmaceutical information, namely the Cancer Cell Line Encyclopedia (CCLE)
[22] and The Genomics of Drug Sensitivity in Cancer (GDSC) Project [23]. Both
consortia have collected the genetic information (gene expression, mutation and copy
number) of 639 cancer cell lines along with their response in 130 anticancer drugs
to investigate their pharmacogenomic interactions. Both consortia used different
sources of samples with a proportion of overlapping cell lines. The results of both
consortia were compared in Stransky et al. [10] leading to the conclusion that their
pharmacogenetic data are fairly consistent despite biological and methodological
factors that may have caused inconsistency. However, data from both resources are
deemed reliable and have been widely used.
Recently, Iorio et al. [9] have investigated gene-drug interactions in a larger
scale as an improvement of the study in [23], with 1,001 cancer cell lines derived
from 29 cancer tissue types and 265 drugs. Different clinically relevant genetic
characteristics of all cell lines, referred to as cancer functional events (CFEs), were
7extracted from gene expression, copy number, and DNA methylation data. With this
information, the authors compared cancer cell lines with primary (patient-derived)
tumours, finding that a large proportion of cancer cell lines recapitulate the genomic
alterations in patient tumours. Furthermore, the authors also suggest best predictors
that associate with drug sensitivity using various methods, and built a logic model
to observe the possible combinations of genetic alterations to drug sensitivity.
The 265 anticancer compounds are largely targeting particular pathways, while a
small proportion (19 compounds, 7.2%) exhibit cytotoxic effects (inhibiting DNA
replication or cytoskeleton) while the rest are targeted agents. These 265 compounds
can be categorised in three stages of clinical development, i.e. clinical drugs (n=48), in
clinical trials (n=76), and experimental drugs (n=141). Each compound was screened
by recording the number of cell population survived at different drug concentrations.
The sensitivity was measured by either (1) IC50 (the drug concentration of an
inhibitor where the response is reduced by half) or (2) the area under the sensitivity
curve (AUC). If a drug is sensitive, the cell population would descend in a faster
rate and results in lower AUC. The data and results were collected to construct a
pharmacogenomics resource, which is now available as the COSMIC and Genomics
of Drug Sensitivity in Cancer Web Portal (www.cancerrxgene.org) and is known to
be the largest portal for cancer cell lines characterisation to date. The summarising
figure of the screened compounds are shown below.
Figure 2: Left: The diagram summarising the targets of screened compounds from
Iorio et al. [9] showing The majority of drugs are targeted in different pathways.
Right: The boxplot shows the number of cell lines screened per compound and vice
versa.
Most anticancer drugs in the GDSC project are majorly targeted, i.e. the drugs
perturb a specific signalling pathway. However, a small proportion of GDSC drugs
exhibit cytotoxic properties (either disrupting DNA replication or cytoskeleton
formation). Figure 2 summarises GDSC drug targets. Furthermore, the diagram
summarising the analysis procedures from Iorio et al. [9] is shown in Figure 3.
With this information, the hypothesis of this thesis is to identify the association
between functional roles of transporters and the drug response. The hypothesis is
8Figure 3: The overview of the analysis pipelines in Iorio et al. [9].
Top panel: Three sources of genetic alterations, i.e. mutations, amplifications and
deletions, and promoter hypermethylation data from 1,001 cancer cell lines were
filtered to capture clinically relevant features. Those filtered data were used as inputs
for discovering the features that associate with drug sensitivity.
Middle panel: The 1,001 cell lines were screened against 265 compounds. The sensi-
tivity for each gene-cell line pair was measured using sensitivity curves, which can
be represented through IC50 or AUC values.
Bottom panel: Associations between genetic profiles and drug sensitivity were identi-
fied using different models.
illustrated in the Figure 4:
9Figure 4: The schematic diagram shows how the effects of influx and eﬄux trans-
porters can be observed from drug sensitivity curve. With the up-regulation of influx
transporters, the drug is more likely to enter the cell and reach its target. This results
in high sensitivity of the drug (low IC50, low AUC, high AOC). In the opposite
scenario, if the eﬄux transporters are up-regulated, the drug is more likely to be
pumped out of the cell, resulting in drug resistance (high IC50, high AUC, low AOC).
However, the up- or down-regulation of a transporter can be directly associated
with the metabolic function (as metabolite transporters), and this can also result in
similar effect. [Figure courtesy of Marc Brehme]
10
3 Research material and methods
3.1 GDSC genomic profiles and drug sensitivity data
Gene expression data
The gene expression data is retrieved from RMA-normalised high quality microarray
experiments. The expression is stored in a matrix of 978 cell lines by 17,419 genes.
To be able to compare the analyses results in tissue level with primary tumour
data from The Cancer Genome Atlas (TCGA)1, cell lines that tissue labels were
unable to identify had been removed from the analysis. The details are shown in the
table below:
Table 1: GDSC Cell lines availability based on TCGA tissue labels. Freq columns
refer to the number of cell lines belonging to each tissue. Note that there are 812
cell lines (out of 1001, 81.2%) being labelled.
Label Description Freq Label Description Freq
ACC Adrenocortical carcinoma 1 LIHC Liver hepatocellular carcinoma 17
ALL Acute lymphoblastic leukemia 26 LUAD Lung adenocarcinoma 64
BLCA Bladder Urothelial Carcinoma 19 LUSC Lung squamous cell carcinoma 15
BRCA Breast invasive carcinoma 51 MB Melanoblastoma 4
CESC Cervical squamous cell carcinoma 14 MESO Mesothelioma 21
CLL Chronic lymphocytic leukemia 3 MM Multiple myeloma 18
COREAD Colorectal adenocarcinoma 51 NB Neuroblastoma 32
DLBC Diffuse Large B-cell Lymphoma 35 OV Ovarian serous cystadenocarcinoma 34
ESCA Esophageal carcinoma 35 PAAD Pancreatic adenocarcinoma 30
GBM Glioblastoma multiforme 36 PRAD Prostate adenocarcinoma 6
HNSC Head and Neck squamous cell carcinoma 42 SCLC Small cell lung cancer 66
KIRC Kidney renal clear cell carcinoma 32 SKCM Skin Cutaneous Melanoma 55
LAML Acute Myeloid Leukemia 28 STAD Stomach adenocarcinoma 25
LCML Chronic Myelogenous Leukemia 10 THCA Thyroid carcinoma 16
LGG Brain Lower Grade Glioma 17 UCEC Uterine Corpus Endometrial Carcinoma 9
Mutation data
The mutation data were taken from the GDSC unfiltered variants catalogue. The
data were collected from the same cell lines as gene expression data. The mutation
data for 416 SLC and ABC gene were extracted. As a result, 17,207 mutation loci
were found.
The mutation is likely random if it was found in only one or a few cell lines. A
threshold of minimum 3 cell lines were set for the loci to be used as an input for the
analyses. This reduces the number of loci to 140.
Drug sensitivity data
265 compounds were screened. The number of cell lines screened for each drug are
various and was represented in Figure 11 (min = 264, median = 692, and max =
746 cell lines). Each drug has different sensitive concentration ranges, resulting in
1Now a part of the Genomic Data Commons (GDC). https://gdc.nci.nih.gov
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diverse IC50 values, which can be difficult to compare. The area under the sensitivity
curve (AUC) was therefore preferentially used. AUC values were normalised to the
range between 0 and 1. However, AUC values are not intuitive to use (low AUC
refers to high sensitivity), the term ‘area over the curve’ (AOC) which is defined as
1-AUC will therefore be used from this point, i.e. low AOC value indicates that cell
lines are less sensitive to the drug.
Some drugs exhibit low response in the majority of cell lines. An example of the
comparison between two drugs are shown below. For quality control in tissue-specific
analysis (described in Section 3.4), these drugs were filtered out from the analysis.
(a) Camptothecin (b) GDC-0449
Figure 5: IC50 comparison of Camptothecin (left) and GDC-0449 (right). These
drug sensitivity plots can be retrieved from the GDSC web portal. The plots show
that the majority of the cell lines are mostly insensitive to GSC-0449 and the drug is
removed from the tissue-specific analysis.
3.2 Detection of tissue specificity enrichment of SLC and
ABC genes
Expression level of transporter genes across multiple cancer tissues can provide
insights on the roles of the transporter to the disease progression. This section
briefly describes the method used for differential expression enrichment analysis for
transporter gene.
Tissue specificity enrichment analysis of a gene is calculated through the moderated
t-test in Limma package in R [11]. The test was performed iteratively for each gene
and each tissue. For each iteration loop, the expression of selected genes were labelled
as 1 if they were from the tissue of interest, and 0 otherwise. Limma performs
hypothesis testing and reports log fold changes, standard errors, t-statistics and
p-values for significance analysis. The reason of using the moderated t-statistics
instead of ordinary t-statistics have been profoundly discussed in Phipson et al. [24]
and the method was proven to be more reliable and has been extensively used in
differential expression analyses.
The ordinary t-test was computed by the scaled mean difference X¯1− X¯2/σ(X1−
X2), so there can be the cases when t-statistics are large accidentally due to small
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within-group variance. Moderated t-statistic has corrected that through empirical
Bayes method (function eBayes in Limma) by introducing the EB moderated variance
estimators that takes into account the degree of freedom of the samples in the test.
In this analysis, the results with FDR corrected p-value of less than 1e-4 were
considered as significant.
3.3 Multiple data integration via joint latent variable model
The topic of integrating multiple data types has been of great interest in biology.
Different biological information are usually collected over the same samples. Being
able to integrate those data would be particularly useful in discovering sub-patterns of
heterogeneous data such as discovering disease subtypes for patient stratification. In
this thesis, a question to be addressed is whether the genetic profiles of transporters
are able to recapitulate the cancer subtypes from the samples. As the data were
acquired from multiple sources, a suitable statistical tool for integrating those data
are of interest to the project.
In general, algorithms for data integration are based on matrix factorisation (MF)
with various sparsity methods imposed. Early methods have limitations such as the
number of datasets allowed in the model, or the datasets were learned separately.
Klami et al. [25] developed a latent variable model aiming to explain the relationship
between groups of variables called Group Factor Analysis (GFA) as an extension to
the well-known factor analysis (FA) model. Flat gamma prior was used to impose
sparsity and implement groupwise relationship. Kirk et al. [26] also developed a
Bayesian joint latent variable model to cluster samples using multiple datasets using
Dirichlet-multinomial allocation (DMA) mixture which can also accommodate time-
series data. The method selected for this analysis is the widely used clustering
method specifically implemented for biological data of different types such as gene
expression (continuous) and mutation data (binary). It was developed by Shen et al.
[12], and is available as an R package called iCluster [13]. The principles of the
method are briefly explained below.
The general factorisation of a matrix X can be written as:
X = WZ +  (1)
Given that X is the mean-centred matrix of genomic profiles of dimension p× n,
and W is the coefficient matrix where dim(W) = p× (K − 1).  = (1, . . . , p)′ is
the error vector in which µ() = 0 and Cov() = Ψ, whereby Ψ = diag(ψ1, . . . , ψp).
Z = (z1, . . . , zK−1)′ is the factor matrix. iCluster utilises the concept of the
K-mean clustering algorithm, where the factor matrix Z is assigned to be indicator
matrix of dimension (K − 1)× n whereby each row represents the indicator vector
of cluster k. The matrix is normalised so that they have a unit Euclidean norm, i.e.
||zk||2 = 1. That is
z′k = ( 0, . . . , 0︸ ︷︷ ︸
cluster 1:k-1
,
1√
nk
, . . . ,
1√
nk︸ ︷︷ ︸
cluster k, length nk
, 0, . . . , 0︸ ︷︷ ︸
cluster k+1:K
) (2)
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nk is the number of samples in cluster k, and
∑K
k=1 nk = n. With this parame-
terisation, the objective function for K-means algorithm can be written, in normal
form and using trace function, as:
min
K∑
k=1
∑
C(i)=k
||xi −mk||2 ≡ min(tr(X′X)− tr(ZX′XZ′)) (3)
Note that with µ(X) = 0, tr(X′X) = Var(X). Therefore, the equation above
refers to variance of the data – variance between the clusters. Since Var(X) is
constant, this is equivalent to maximising the variance between groups:
max
ZZ′=IK
tr(ZX′XZ′) (4)
Let us assume there are m types of input datasets, each data type denoted
as Xi where i = 1, . . . ,m, and the factorisation form can therefore be written as
Xi = WiZ + i. Note that the factor matrix Z is jointly learnt for all the data types.
In biological context, Z would refer to the molecular subtypes of the samples. On
the other hand,  is an independent error term and represents the unique variance of
the data.
To be able to solve the equation above using maximum likelihood estimation
(MLE) of Gaussian latent variable model, Z needs to be approximated into continuous
values. This way would unfortunately reduce the interpretability in terms ofK-means
clustering, but would also reduce the complexity of finding the optimal Z. Let Z∗ be
defined as the continuous parameterisation of Z while assuming that Z∗ ∼ N (0, I)
and  ∼ N (0,Ψ); with this assumption, the input matrices can be written in the
form of multivariate Gaussian as follows:
X = (X1, . . . ,Xm)′ ∼ N (0,Σ) (5)
where Σ = WW′ + Ψ.
The method employs EM algorithm to compute the complete data log-likelihood:
`(W,Ψ) =− n2
(
m∑
i=1
pi log(2pi) + log det(Ψ)
)
− 12
(
tr((X−WZ∗)′Ψ−1(X−WZ∗)) + tr(Z∗′Z∗)
) (6)
iCluster sets sparsity by adding Lasso regularisation term (see in section 3.4)
to the log-likelihood function (Equation 6), controlled by parameter λ. In this
analysis, the non-sparse solution (λ = 0) as well as the sparse solution (λ = 0.01)
were compared, while a range of K values were tested to observe how samples are
clustered together. The data used as the input are the expression of 416 transporter
genes and their mutation profiles.
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3.4 Feature selection: detection of significant gene - drug
pairs
Biological data in general are heterogeneous and the distribution of expression of a
gene across different samples is rather inconsistent, making them difficult to analyse
with a particular method and to draw conclusions from their results. Multiple
methods listed below were chosen to capture the relationships in different ways with
different levels of complexity aiming to identify the strong relationships for gene-drug
pair candidates.
Correlation test
The calculation of correlation coefficients is based on an assumption of data being
normally distributed. However, the correlation test has been proven to be a simple
yet powerful tool to identify the association among variables despite the non-uniform
nature of data. The analyses in this study were done in both pan-cancer and
tissue-specific manners. cor.test function in R was used to calculate Pearson and
Spearman correlation coefficients for each gene-drug pair and their associated p-value.
For pan-cancer analysis, the correlation test was performed in all possible com-
binations of genes and drugs. The correlation coefficients along with p-value from
correlation test were stored. The p-values were FDR corrected and those with p-value
of less than 1× 10−3 were identified as significant.
Tissue-specific analysis is relatively more difficult. The analysis suffers from both
the amount of cell lines in each tissue and the poor sensitivity of the majority of cell
lines in that tissue for some drugs. Therefore, a threshold was set for a drug to be
used in the test for each tissue type as follows:
For a drug to be analysed in a particular cancer type, there must be
1. at least 8 cell lines being screened. Preliminary analysis found that the correla-
tion test of fewer than 8 samples are not reliable.
2. those cell lines must constitute to at least 20% of all number of cell lines in the
tissue type.
3. at least 3 cell lines having IC50 below the maximum concentration of the drug.
This is biological filtration of the data. If the majority of the cell lines in the
tissue are insensitive to a drug, then the drug-tissue pair was removed from
the analysis to avoid false conclusion.
Analysis of Variance
The analysis of variance (ANOVA) of a gene-drug pair were performed to observe the
significance of the drug response between the groups. The groups here are defined as
samples with high and low expression levels. The main issue for using this method is
that the gene expression levels were originally represented as continuous values, and
two mixture models were unsuccessful to categorise the samples. An easy but robust
way to perform this analysis is to consider cell lines with top 10% of expression
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levels as ‘highly expressed’ and the bottom 10% as ‘lowly expressed’. The samples
in between those two ranges were neglected. Ordinary t-test was then performed
to the binarised samples, with the tissue effect taken into account as a covariate
(control variable) of the analysis. However, due to the 80% loss of samples during
binarisation, an alternative method based on k-mean clustering was proposed in
Chapter 5.
Linear model with regularisation
To apply linear models, the relationship between independent variables (drug sensi-
tivity, AOC) and dependent variables (gene expression) in this analysis was assumed
to be linear. The common problem here, which is similar to other data-driven
biological analyses, is the high dimensional feature space (p >> N problem). To
avoid overfitting, linear model with regularisation was introduced to select most
relevant features.
The two most renowned regularisation methods are Ridge and Lasso (least
absolute shrinkage and selection operator) regularisation. Ridge uses `2 penalty
term, limiting the size of the model coefficients while Lasso uses `1 penalty, imposing
sparsity to the coefficient matrix and hence the model is more interpretable. From
Bayesian point of view, Ridge regression is equivalent to the case when coefficients
are assigned to normal prior distribution while Lasso has Laplace prior which are
sharply peaked at their means.
The illustration comparing Ridge, Lasso, and elastic net regularisation is sum-
marised in Figure 6:
(a) (b) (c)
Figure 6: Geometrical representation of different regularisation methods. Figure 6a
shows two-dimensional space geometrical representation of Lasso (left) and Ridge
(right) regularisation. The contour shows the regularisation path as the optimal βˆ is
regularised. Lasso regularisation applies `1 penalty, allowing the contour to reach the
axis and imposing sparsity. The Ridge regression follows `2 penalty and therefore
sparsity cannot be imposed. [Figure from Bishop [27]]. Figure 6b illustrates the
geometrical representation of Lasso, Ridge, and Elastic Net, which is the combination
of `1 and `2 penalty [28], and Figure 6c is the Bayesian representation of Lasso
regularisation as having Laplace prior distribution.
Consider the standardised predictor matrix X of dimension n× p and Y as the
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n-vector of observation. The Lasso regularisation follows:
min
β
||Y −Xβ||2 subject to ||β||1 6 t (7)
Where t is a parameter determining the amount of regularisation and ||Z||p =(∑N
i=1 |Zi|p
)1/p
is the `p norm.
The equation 7 can be rewritten by introducing Lagrange multiplier λ as:
min
β
{
||Y −Xβ||2 + λ||β||1
}
(8)
However, Lasso is greatly limited by the number of samples. In p > n cases, Lasso
only selects at most n variables. While this can be sufficient for the task, Elastic
net regularisation was instead used for this analysis. Elastic net was developed by
Zou & Hastie [28] by adding Ridge penalty term to Lasso. Elastic Net can usually
outperform Lasso in p > n cases and can select correlated predictors together, which
were the advantage of Ridge regression.
The Elastic net modified the Equation 8 by adding Ridge penalty term, which is
to solve:
min
β
{
||Y −Xβ||2 + λ
[
(1− α)||β||22/2 + α||β||1
]}
(9)
The Elastic net regression was implemented in R in the package glmnet [29].
The equation 9 was solved over a range of λ. The trade-off between Lasso and Ridge
is controlled by α, where the default value is α = 1, and therefore the model follows
Lasso regularisation. This value can be adjusted to have a lower value (min=0)
to add Ridge penalty term. In this analysis, 10-fold cross validation was applied.
glmnet returns two values of λ, the lambda.min which refers to value of λ at the
lowest cross validation error and lambda.1se, the λ in the range of 1 standard error
from lambda.min but returned more regularised and therefore results in simpler
model. In this analysis, the result from lambda.1se was compared with lambda.min
and the results are discussed.
3.5 Learning the transporter interactions during drug in-
take via hierarchical group-Lasso
Two or more transporters may function together in drug uptake. Their individual
effect may not be strong enough to capture in Lasso or Elastic net regularisation, so
a method for interaction learning among predictors are therefore one focus of this
thesis.
The topic of interaction learning is an active study field. Logic regression [30],
for example, finds the interaction relationship by using boolean combinations of
most predictive features, e.g. (G1 ∧ G2) ∨ G3, where Gi indicates arbitrary gene.
This method is capable of discovering higher order (i.e. more than two features)
interactions, but it is limited to binary variables and cannot directly be applied in
this case.
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Most of the interaction learning methods that can accommodate continuous
variables where scalability is an issue are penalty-based. The method used in this
analysis is hierarchical group-Lasso regularisation [14]. The method can model
pairwise interactions of both categorical and continuous variables.
Biological data is generally acquired by collecting several attributes of samples
whereas the number of samples are much lower (“p >> n” problem). By modelling
interaction among the features would further increase the size of the feature space to
p +
(
p
2
)
. For 416 SLC and ABC genes of interest, the total number of features in
the model was over 100,000. The method proposed by Lim & Hastie [14] is called
GLINTERNET which is based on group-lasso regularisation. With p in this order of
magnitude, the model can directly be applied to all variables. However, larger scale
of p may need variable screening to reduce the dimension first.
Let the feature space denoted as X, and Xi:j represents the interaction vector
Xi ∗Xj. The multiplication applies in element-wise manner for each row, i.e.
Xi ∗Xj =

x1i
...
xni
 ∗

x1j
...
xnj
 =

x1ix1j
...
xnixnj
 (10)
Imposing hierarchy to first-order interaction model
Hierarchy for interaction model refers to the dependency of interaction effects to the
presence of main effects. GLINTERNET was considered as a suitable method in this
analysis partly because the model obeys strong hierarchy. Strong hierarchy is the
case when an interaction is detected only if its main effects are present. To put it in
biological context of this thesis, this makes sense to assume that two transporters
that act together are those that individually affect the drug sensitivity, but their
combination effect was unknown, or was not strong enough.
In general, the first-order interaction can be modelled by adding the additional
interaction terms to the linear model:
Y = β0 +
p∑
i=1
Xiβi +
∑
i<j
Xi:jβi:j (11)
The algorithm applies group-Lasso regularisation, the more general version of
Lasso to distinguish main and interaction effects and to be able to impose hierarchy.
Assume the variables are divided into groups. Let denote p as the number of groups
of features that do not necessarily be of the same size, and Xi are the feature matrix
of group i. The group-Lasso estimates the optimal coefficients β by modifying Lasso
(equation 8) into:
argmin
β,β0
12 ||Y − β0 · 1−
p∑
j=1
Xjβj||22 + λ
p∑
j=1
γi||βj||2
 (12)
The optimal coefficients βˆj can be obtained, and similar to the previous cases, λ
controls the regularisation. The term γ were added to adjust the group penalty. In
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this case, γj = 1 ∀j for simplicity. GLINTERNET generates a range of λ to apply to
the model, starting from a very large one to regularise most of the variables away. It
is often observed that the choice of λ selected from this algorithm can be too large
that several sets of λ values needed to be generated. The optimal λ values are found
through cross validation. In this study, 10-fold cross-validation was used.
Overlapped group-Lasso
Overlapped group-Lasso is group-Lasso that allows a variable to be in different groups.
The overlapped group penalty imposing strong hierarchy is added to equation 12.
GLINTERNET has been formulated by using overlapped group-Lasso so that it could
accommodate multi-level categorical data. In this analysis, the variables (gene
expression) are continuous.
The generalisation of Equation 10 is given by:
X1:2 = [1 X1] ∗ [1 X2]
= [1 X1 X2 (X1 ∗X2)]
(13)
The linear model for the interaction of continuous variables is the extension of
Equation 8 and 12, which follows:
argmin
β
1
2 ||Y−β0·1−X1β1−X2β2−([1 X1]∗[1 X2])β1:2||
2
2+λ(||β1||2+||β2||2+||β1:2||2)
(14)
For this analysis, GLINTERNET was performed to each response vector (sensitivity
for one drug) without variable screening. The results are discussed in the next
chapter.
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4 Results
4.1 The Landscape of Transporter Expression
Transporter genes are expressed differently in different tissues. The information
of which tissues a specific transporter is mostly expressed have been well studied
and collected in www.bioparadigms.org. However, the landscape of transporter
expression in cancer, which can be different from normal tissues, has not been
well investigated and this could further connect to tumorigenesis and consideration
for choices of treatment. For instance, knowing which transporters are excessively
expressed in the tissue of interest can lead to appropriate selection of drugs that
found to be specific to the transporter.
4.1.1 Tissue-specific patterns of SLC and ABC transporters
To get a glimpse of how transporters are differently expressed in different tissues,
the heatmap showing average expression level of all the cell lines in each tissue are
shown for SLC and ABC genes in Figure 7.
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Figure 7: The heatmap of SLC expression and ABC expression level in different
tissues. Each cell represent the average expression level of the gene (row) and cancer
tissue (column). The SLC expression profile shown in left panel while ABC are
shown in right panel. The rainbow on the left of each panel represents the tissue
colour code.
The column of the data is clustered using Euclidean distance. The leftmost
columns of both panels show transporters that are widely expressed in the majority
of samples, thus they exhibit ‘house keeping’ properties. Those cases are particularly
interesting since under-expression of genes that are normally highly-expressed might
be associated with cancer progression.
The identification of tissue-specific transporters were calculated by moderated
t-test with FDR corrected p-values through package Limma in R (details in Section
3.4). Since the algorithm provides several candidates with low p-values, the threshold
for significance is p-value < 1e-20.
In Figure 8, the results from differential expression analysis of SLC and ABC
genes were shown. The corresponding table of this analysis was included in Appendix
A.
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(b) ABC differential expression analysis
Figure 8: The scatter plot of differential expression analysis for each tissue type of
SLC and ABC genes. Each point represents a gene-tissue pair and the plot shows
-log(p-value) against the log fold change of the expression for each gene-tissue pair.
There are notable cases, especially those conferring under expression, which are
genes that are normally highly expressed. An example is the under expression of
TAP1 gene in neuroblastoma (NB) and small-cell lung cancer (SCLC), as shown in
the left side of Figure 8b. TAP1 is the transporter associated with antigen processing;
and it is required for the histocompatibility complex (MHC) class I pathway. MHC I
is important for tumour surveillance, and the lack of this pathway has been linked to
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tumorigenesis in neuroblastoma [31] [32] [33]. Similarly, lack of TAP1 in lung cancer
(SCLC) have led to the same effect [34]. This further indicates the endogenous roles
of transporters in cancer as suggested in Nigam [15].
While low expression of particular genes in ABC family are well documented,
literature supports for similar cases in SLC genes were still largely insufficient. The
analysis found underexpression of SLC38A1 in SKCM, SLC10A3 and SLC25A43 in
SCLC, SLC16A1 in BRCA, and SLC35D2 in DLBC. Not many strong evidences to
support the roles of these transporters in cancer progression were found.
In the opposite cases, there are significantly more tissue-specific genes exhibiting
over expression. The strongest case found is SLC45A2 in skin cancer (SKCM), which
has been supported by recent literatures about SLC45A2 involvement in pigmentation
pathway is a strong risk factor in melanoma [35]. Other recent studies also confirmed
the importance of transporter SLC24A5 in controlling pigmentation in different
ethnicities [36] [37]. Over expression of this gene is therefore likely to induce effects
that lead to melanoma.
There are other several cases that differential expression have been captured in
this analysis and their association to tumour progression have been known, while
there are also many others, which their effect might not be as strong, but this could
provide further novel insights into more detailed studies of these transporters and
their roles in tumorigenesis.
4.1.2 Recapitulation of cancer subtypes characteristics based on multi-
ple genetic profiles
Two data types, i.e. (1) standardised gene expression profiles of 416 SLC and ABC
genes and (2) cancer functional events (hypermethylation and copy number variations)
in binarised format were used as the input to compute the common factor loading Z
using Equation 6 via iCluster in R.
The Figure 9 below shows the results of cancer cell lines clustering when assigning
k = 30 and the algorithm performed in 50 iterations. The row represents true cancer
subtypes, while the column represents 30 clusters from the algorithm. This is
to observe how well transporter genetic profiles are able to recapitulate cancer
heterogeneity, and which cancer tissues have distinct transporter expression patterns
than the others.
From this analysis, it can be seen that cell lines in breast, skin, and large intestine
show relatively strong transporter tissue specificity pattern, with more than 50% of
all cancer cell lines in the tissues were assigned to the same cluster. This can lead
to a hypothesis that SLC and ABC transporter genetic profiles in these tissues are
able to recapitulate the cancer tissue characteristics more than other tissues. This
can lead to a hypothesis of whether transporters in these tissues play more roles in
tumorigenesis than the rest of the tissues.
The concept of matrix factorisation can further be applied by assigning k = p,
and a cell line will belong to one cluster. Weight matrix in that scenario can be used
for further prediction instead of gene expression profile themselves.
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Figure 9: Cluster results from iCluster using k = 30 with 50 iterations. The
number in each cell represents the percentage of cell lines for each cancer tissue (row)
belonging to a cluster (column). Three cancer tissues i.e. breast, skin and large
intestine show strongest within-tissue clusters.
4.2 The Transporter - drug association
4.2.1 Correlation analysis of drug-transporter association
Despite both of the independent (gene expression) and dependent (drug response)
data are not normally distributed, simple correlation analysis has been proven
useful in identifying significantly correlated patterns. This correlation analysis was
performed in both pan-cancer and tissue-specific manner.
Pan-cancer correlation analysis
This Pearson’s correlation test for each drug was performed to all genes. The
correlation is identified as significant if the drugwise FDR corrected p-value of the
test is smaller than 1e-3. Drugs with SLC or ABC genes identified as significant
were shown in the boxplot below in Figure 10, and the corresponding information
from the correlation test for those labelled genes in Figure 10 is shown in Table 2.
Tissue-specific correlation analysis
Tissue-specific analysis has to encounter the issue of insufficient sample size. With
the criteria described in Chapter 3, several drugs have been discarded from specific
tissues. The heatmap showing availability of data for each tissue is shown in Figure
11.
There are 46 drugs that have been discarded from the tissue-specific analysis due
to insufficient sample size. The names of those drugs are listed in Table 3.
The correlation test was performed to gene-drug pairs in all available tissues
that met the criteria discussed in Section 3.4, resulting in over 1 million correlation
outcomes generated. The FDR corrected p-values were performed for each drug, and
the significant pairs are those with p-value lower than 1e-3.
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Figure 10: Boxplot shows standardised (z) values for correlation coefficients of all
17,419 genes for each drug. Out of 265 drugs. 14 drugs with SLC or ABC genes
identified as significant are shown.
The significant associations were listed in the Table 4, sorted by tissue names.
It was found that most significant associations identified have positive correlation
coefficients, therefore conferring drug sensitivity.
Text mining was attempted to retrieve number of publications in PubMed con-
taining the tissue, drug, and gene names in the list. However, there are variants of
the names and many drugs are in investigational phases. The retrieval of number of
publications as a support of the findings are therefore not trivial.
Note that the tissue-specific analysis was not applied in other association detection
methods due to the sample size issues.
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Table 2: Corresponding gene-drug associations for Figure 10.
Gene Name Drug Name z-value FDR Effect
ABCB1 Vinorelbine -5.808 1.2E-06 resistant
SLC16A7 DMOG 6.288 1.4E-06 sensitive
SLC9A2 Ruxolitinib 4.628 6.5E-04 sensitive
ABCB1 AT-7519 -5.702 3.3E-05 resistant
ABCB1 WZ3105 -7.394 8.7E-11 resistant
SLC16A1 CP724714 -4.253 2.0E-04 resistant
ABCB1 YM155 -4.773 2.6E-04 resistant
SLC35F2 YM155 5.236 6.7E-05 sensitive
SLC35F2 NSC-207895 5.202 3.3E-05 sensitive
ABCB1 Vinblastine -4.402 1.8E-04 resistant
ABCB1 ZG-10 -5.660 6.5E-06 resistant
ABCG2 ZG-10 -5.338 3.5E-05 resistant
ABCB1 QL-VIII-58 -6.815 1.4E-12 resistant
SLC35A2 Bleomycin (50 uM) -3.268 6.6E-04 resistant
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Figure 11: Tissue-specific analysis suffers from insufficient sample size. Tissue-drug
pairs that the correlation tests were not performed are shown in red. A number of
drugs were entirely discarded from the analysis.
Table 3: Drugs that were removed from the tissue-specific analysis due to insufficient
sample size.
NSC-87877 Bicalutamide CHIR-99021 FTI-277 LFM-A13 GW-2580
BMS-708163 Ruxolitinib CP724714 Zibotentan KIN001-055 AV-951
Olaparib ABT-888 SB 216763 VX-702 AMG-706 Vismodegib
JNK Inhibitor VIII CCT007093 EHT 1864 BMS-708163 PF-4708671 AG-014699
Tamoxifen IOX2 UNC1215 SGC0946 XAV 939 Temozolomide
PHA-665752 Cyclopamine Imatinib Crizotinib GNF-2 KIN001-135
Bryostatin 1 GSK-1904529A XMD15-27 EX-527 SL 0101-1 BIRB 0796
XMD11-85h SB-505124 Bicalutamide Erlotinib
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Table 4: The result from correlation test for tissue-specific correlation analysis.
Tissue Drug name Gene ρ df adj. p-val z Effect
ALL PLX4720 SLC13A4 0.858 21 9.2E-05 3.255 sensitive
ALL PLX4720 SLC26A3 0.891 21 2.0E-05 3.382 sensitive
ALL PLX4720 SLC28A3 0.877 21 3.2E-05 3.329 sensitive
ALL PLX4720 SLC9A5 0.809 21 9.8E-04 3.068 sensitive
ALL PLX4720 ABCA13 0.851 21 1.1E-04 3.227 sensitive
BRCA RDEA119 SLCO3A1 0.842 41 1.4E-08 3.428 sensitive
BRCA BMN-673 SLC7A7 0.784 43 2.1E-06 3.458 sensitive
BRCA BMN-673 SLC51B 0.706 43 2.1E-04 3.120 sensitive
BRCA BMN-673 SLC12A3 0.764 43 5.4E-06 3.373 sensitive
BRCA Trametinib SLCO3A1 0.697 43 7.4E-04 2.980 sensitive
BRCA AS605240 SLC18A1 0.679 45 5.2E-04 3.253 sensitive
BRCA RDEA119 ABCB1 0.799 41 6.4E-07 3.251 sensitive
BRCA PD-0325901 ABCB1 0.722 40 3.1E-04 2.995 sensitive
BRCA Trametinib ABCB1 0.690 43 7.4E-04 2.952 sensitive
BRCA AS605240 ABCB1 0.774 45 1.8E-06 3.701 sensitive
COREAD Temsirolimus SLC6A15 0.723 39 9.2E-04 3.196 sensitive
COREAD GSK1070916 SLCO1C1 0.687 42 9.5E-04 3.061 sensitive
COREAD Sunitinib SLC4A4 0.939 13 9.5E-04 3.472 sensitive
COREAD YM155 ABCB1 -0.738 43 7.5E-05 -3.290 resistant
DLBC KIN001-270 SLC52A3 0.788 25 1.1E-04 2.857 sensitive
DLBC KIN001-270 SLC26A3 0.862 25 3.3E-06 3.145 sensitive
DLBC KIN001-270 SLC44A4 0.802 25 6.7E-05 2.913 sensitive
DLBC KIN001-270 SLC44A3 0.766 25 2.2E-04 2.772 sensitive
DLBC KIN001-270 SLC9A2 0.774 25 1.8E-04 2.802 sensitive
DLBC KIN001-270 SLC47A1 0.842 25 7.8E-06 3.067 sensitive
DLBC NVP-TAE684 SLC26A4 0.841 22 7.8E-04 3.166 sensitive
DLBC BMS-536924 SLC51B 0.913 21 6.2E-06 3.368 sensitive
DLBC KIN001-270 ABCC3 0.737 25 7.0E-04 2.656 sensitive
DLBC NVP-TAE684 ABCC9 0.841 22 7.8E-04 3.166 sensitive
LAML ATRA SLC47A1 0.868 22 6.4E-05 3.314 sensitive
LAML Dasatinib SLC4A8 0.844 24 3.0E-04 3.022 sensitive
LAML A-770041 SLC44A5 0.916 24 2.6E-07 3.141 sensitive
LAML A-770041 SLC35F4 0.903 24 6.9E-07 3.097 sensitive
LAML A-770041 SLC4A8 0.806 24 8.6E-04 2.769 sensitive
LAML A-770041 SLC4A4 0.832 24 2.3E-04 2.859 sensitive
LCML Nilotinib SLC10A2 -0.974 8 7.7E-04 -3.296 resistant
LCML Nilotinib ABCA6 -0.981 8 5.0E-04 -3.318 resistant
NB RDEA119 ABCC3 0.843 26 6.0E-05 3.428 sensitive
NB CI-1040 ABCC3 0.906 25 7.6E-07 3.743 sensitive
NB PD-0325901 ABCC3 0.851 26 9.0E-05 3.532 sensitive
NB AS605240 ABCC3 0.862 25 3.7E-05 4.121 sensitive
NB LY317615 ABCC3 0.842 25 3.7E-04 4.061 sensitive
OV ABT-263 SLC12A3 0.797 30 2.8E-04 3.344 sensitive
OV Afatinib (rescreen) SLC23A2 0.787 30 3.4E-04 3.607 sensitive
OV GSK-650394 ABCD2 0.912 16 7.1E-04 4.084 sensitive
SCLC GSK-650394 ABCA10 0.656 49 7.1E-04 2.915 sensitive
SKCM MP470 SLC16A8 0.812 48 3.9E-09 3.422 sensitive
STAD AZD6244 SLC2A2 0.910 18 2.1E-04 4.090 sensitive
STAD MP470 ABCC9 0.967 18 8.6E-09 4.099 sensitive
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4.2.2 The analysis of variance (ANOVA)
The ANOVA results for ABC and SLC genes are shown in the figure 12.
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Figure 12: The ANOVA results, separately analysed for SLC and ABC genes. Each
dot represents the gene-drug association pair, plotted in FDR adjusted p-value against
Cohan’s effect size. Associations marked in red are the pairs that confer resistance
while the ones in green are those that confer sensitivity. The grey dots represent
association below the significant threshold (20% FDR). [Figure courtesy of Mi Yang]
The ANOVA results from Figure 12 shows that ABC genes are more strongly asso-
ciated with drug resistance, with ABCB1 and ABCG2 appear to be most significant
to several drugs.
In contrast, SLC genes do not exhibit strong effect towards drug resistance or
sensitivity, with the number of association pairs in both cases are relatively equal.
This result contradicted earlier assumption by previous studies of SLCs that they
majorly act as influx transporters, i.e. they mediate drugs to enter the cell.
The list of top hits identified in Figure 12 were summarised in Table 5 below with
drugs having similar effects to the same genes represented together.
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Table 5: Top hits from ANOVA, categorised by the drug that each gene confer
sensitivity and resistance
Gene Top sensitives Top resistants
SLC20A1 AZ628, Trametinib –
SLC9B2 SNX-2112, THZ-2-102-1 –
SLC16A7 DMOG –
SLC25A24 Docetaxel –
SLC6A18 CUDC-101 –
SLC35F2 YM155 –
SLC35D3 – Z-LLNle-CHO, Bortezomib
SLC19A2 – HG-6-64-1
SLC38A5 – TGX221
SLC18A1 – Bleomycin , Docetaxel
SLC25A1 – UNC0638, MPS-1-IN-1, PXD101, Belinostat
4.2.3 Feature rankings with Elastic Net regularisation
The question to be addressed from this section is, which transporters, if any, are
most associated with the drug response profiles. In addition to the previous methods,
linear regression with regularisation was applied with the feature space containing
416 SLC and ABC transporter genes.
One of the issues observed is that the optimal regularisation parameter (λ) is not
found. The plot of cross validation error against λ values are shown below for three
drugs to show all possible behaviours of the models.
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Figure 13: Mean squared error (MSE) value against λ plot for three drugs. As a
higher value of λ applied, the model is more regularised and the coefficients of many
features are set to zero. The λ values that can be returned from the algorithm is the
λmin, which is the value when mimimum MSE is reached (vertical dotted line on the
left of each plot), and the λ1se, the more regularised value, shown in vertical dotted
line on the right.
In Figure 13(a), the value of λmin was found, with the λ1se does not regularise all
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features while Figure 13(b) is the case when λ1se regularise all features, indicating
that the optimality of λmin is not significant. Figure 13(c) is the scenario when λmin
is not found, and no features were reported from the model.
Using λ1se as the regularisation parameter for all models, there are only 10 drugs
(out of 265) that the model returns associated features. On the contrary, models
with λmin as regularisation parameters are less regularised and up to 161 drugs have
associated features. The results of both models are shown in Figure 14a and Figure
14b. With the higher stringency of the model with λ1se, the results can be considered
as more reliable.
The analysis in Figure 14a, despite not showing many drugs, it supports known
functions of ABCB1 as a multidrug resistance transporter, with it appeared to be
the only transporters selected from the model in several drugs. Similarly, the results
shown in Figure 14b shows similar effects, with ABCB1 ranked as the most associated
transporters to several drugs. However, new information obtained from this analysis
is the sensitivity of several drugs to SLC35F2 (shown in the rightmost column). It
was known to be associated with YM155, which was also captured from the model,
but it has never been known before that SLC35F2 were found sensitive in many other
drugs (it ranked top 3 in 11 drugs). This can lead to further hypothesis of ‘multi-drug
sensitivity transporter’ of SLC35F2, in the contrary to the property observed in
ABCB1. Further analyses of the function of the transporter and the structures of its
associated drugs will be needed to investigate and confirm this observation.
Figure 14b also represents several transporters associated to some drugs. This
can be hypothesised either as (1) it suggests the redundancy of transporter functions,
with a drug do not necessarily be associated to a particular transporter, or (2) they
function cooperatively. To capture the dependency of two transporters for drug
intake, the identification of transporter interactions will be discussed in the next
section.
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Figure 14: Elastic Net feature selection results from λ1se and λmin as regularisation
parameters respectively.
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4.3 Interaction of multiple transporters in drug response
This section aims to disclose the information of two transporters that cooperatively
mediate drug sensitivity or resistance, i.e. their effects are dependent on each other.
This can be the case when, for instance, a drug needs to reach its target in a
membraned organelle (e.g. nucleus, vesicle or ER), so it needs two transporters that
associate with a drug (one at the cellular membrane and the other is at the organelle
membrane), or when two transporter genes encode for proteins that function together
as a complex. This association of transporter to drug sensitivity will from this point
be referred as ‘interaction’.
The first-order interaction among transporters were identified via GLINTERNET
with default setting of the package. The algorithm reports main effects as well
as interaction effects for each drug. Among 265 drugs, there are 109 drugs that
interaction between two transporters were captured. The graph representation of all
interaction detected from the algorithm of all drugs is shown in Figure 15.
gene1 gene2 n drugs
SLC6A11 SLC6A12 10
ABCC8 ABCC9 9
SLC5A12 SLC7A9 8
SLC20A1 SLC26A7 7
SLC1A3 SLC3A1 7
SLC20A2 SLC41A2 7
SLC25A20 SLC37A2 6
SLC6A6 SLC7A11 6
SLC41A2 SLC9A5 6
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Figure 15: The landscape of transporter interactions from GLINTERNET with default
hyperparameter settings, represented in graph.
In Figure 15, nodes represent genes with their sizes correspond to the number of
interacting pairs. The colour of each node represents whether the gene belong to
SLC (yellow) or ABC (orange) superfamily. Two genes are connected by an edge
if the interaction between them is detected, and the width of an edge corresponds
to the number of drugs the interaction is found. The table on the left of the figure
shows top 20 transporter interaction pairs, sorted by the number of drugs that the
interaction is detected.
Some interacting pairs are transporters in the same family, e.g. SLC6A11 and
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SLC6A12 found to be associated to 10 drugs, and ABCC8 is associated with ABCC9 in
9 drugs. These cases may be resulted from the complex formation of the transporters
that transport function required the presence of both genes. On the contrary, there
are notably high number of interacting pairs from transporter genes in different
families. Many of them are isolated pairs (two nodes connected with an edge in
Figure 15) while many can be represented as connected graph. SLC7A11 confers
resistance to several drugs from the association analyses in the previous section, it is
found to be highly associated with SLC6A6 which had not been detected in other
previous sections. SLC7A11 also found to be a hub of a cluster, similar to SLC16A2,
SLC6A16, and SLC18B1. These interaction information can be useful for additional
information to concern in drug discovery to improve the efficacy of a drug.
32
5 Discussion and Outlook
5.1 Further landscape analyses to disclose transporter het-
erogeneity
In Chapter 4, the analyses in the matrix factorisation part were focused onto tumour
heterogeneity given transporter information. The clustering can be done in the
opposite way, i.e. using multiple datasets of the same set of transporter genes. With
this formalisation, latent variable matrix for the combination of gene expression
databases, e.g. GDSC and CCLE can be done. Shared information among the
multiple data types will be captured and this might improve the accuracy for further
analysis with drug efficacy association.
The tissue specificity identified in the previous chapter provide the information
obtained from cell lines. To be able to draw a conclusion in clinical context, the
comparison of transporter expression in cell lines (GDSC) need be compared with
the primary tumour databases (samples extracted from patients from The Cancer
Genome Atlas, TCGA). By doing so, the agreements between cell lines and patient
transporter landscape information can be observed, and this can pinpoint whether
effects observed in cell lines are likely to be the same in patient levels.
5.2 Gene-drug association top hits agreements among dif-
ferent methods
To systematically confirm the gene-drug association, experimental validation is
required to ensure the effect of a transporter to drug sensitivity.
With various limitations and sensitivities of different association detection methods
used in this project, the results obtained from each method can be very different.
The list of candidates for experimental validation should therefore be the significant
top hits that appear across multiple methods.
The list of top hits that were identified as significant in more than one method is
shown below.
Table 6: Significant top-hits from multiple methods and their novelty level. In the
Effect column, S and R are abbreviated from ‘Sensitive’ and ‘Resistant’, respectively.
The methods included here are Pearson’s correlation test (CT1), Spearman’s correla-
tion test (CT2), Analysis of Variance (ANOVA), Elastic Net model using all genes as
features (EN1), and Elastic Net model using SLC and ABC genes as features (EN2)
Gene Drug CT1 CT2 ANOVA EN1 EN2 Effect Novelty
SLC16A7 DMOG 3 3 3 3 3 S Novel
SLC35F2 YM155 3 3 3 3 3 S Studied in [18]
SLC35F2 NSC-207895 3 3 3 S Novel
SLC7A11 (5Z)-7-Oxozeaenol 3 3 R Novel
SLC7A11 piperlongumine 3 3 R Mentioned [38]
SLC9A2 Ruxolitinib 3 3 S Novel
SLC16A1 CP724714 3 3 R Novel
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From the Table 6, there are only two hop hits which were in agreement with all
methods, which are SLC35F2-YM155 and SLC16A7-DMOG. The first association
pair has thoroughly been studied in Winter et al. [18] and it was found that the
sensitivity of YM155 reduced significantly when SLC35F2 was knocked out. However,
similar analyses for SLC16A7 and DMOG has not been found.
Furthermore,it was found that many other drugs has reported high sensitivity with
SLC35F2 (as represented in Figure 14b). The most notable case here is NSC-207895,
which the association can be captured in three methods and this association has also
not been known.
SLC7A11 is also another SLC transporter that confer resistance with several
drugs, where most of their associations were captured in Elastic Net model, and
therefore could be a potential candidate to detailed studies of the multiple drug
resistance functions of transporters in SLC superfamily.
5.3 Interaction learning
The interaction terms may be modified as follows.
By the formalisation of interaction term in the Equation 13, the interaction terms
are in different order of magnitude to the main features and their coefficients are
therefore not comparable. The proposal of interaction term formalisation as an
alternative to 13 would be
X1:2 = [1 X1/21 ] ∗ [1 X1/22 ] (15)
where X1/2i indicates the element-wise square root operation,
i.e. if Xi =

x1i
...
xni
, then X1/2i =

x
1/2
1i
...
x
1/2
ni

5.4 Issues with binarisation of gene expression
Several methods require either the input or the response data to categorical, e.g.
ANOVA requires the input vector to be discretised, while logistic regression requires
the response vector to be discretised. However, both gene expression and drug
sensitivity were measured as continuous values, appropriate methods were required
for discretisation. ANOVA results in Chapter 4 was done by considering top 10% of
expression level in all cell lines as ‘sensitive’ and the bottom 10% as ‘resistant’. While
this might ensure the difference of two groups of cell lines, 80% of the cell lines were
discarded and the criterion does not truly reflect the actual distribution of the data,
and this could lead to fault results. Probabilistic-based clustering methods such
as Gaussian mixture model cannot be applied as it assumes that the data follows
a particular distribution. The unsupervised and simple method such as k-means
clustering algorithm can be the improvement for further analysis (k = 3). The cell
lines were clustered into three groups, and the middle group are considered ambiguous
and were not assigned to any cluster. This method would reduce the number of cell
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lines discarded, while clustering the cell lines with taken their statistical information
into account. Preliminary analysis of gene expression data with different probability
densities is shown below in Figure 16.
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Figure 16: The density estimation of 4 genes is shown to show the behaviour of
k-mean clustering algorithm when assigning k = 3 with Gaussian kernel applied.
Data points displayed in red are labelled as ‘not expressed’ while data points labelled
in green as ’expressed’. The data points in grey area are discarded from the analysis.
This method, however, can suffer from the imbalanced number of cell lines in
each cluster. This can happen when a gene has extremely high expression level in
a few cell lines, k-mean clustering tends to cluster those few cell lines in the same
cluster.
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6 Summary
Cellular transporters are gateways that allow small molecules, including drugs, to
enter the cells. Several studies have already shown that drug efficacy can largely be
determined by expression levels of particular transporters [18] [19] [6]. Evidences
suggesting that toxicity and efficacy issues, which are two major concerns in drug
discovery, are likely due to the lack of understanding of drug absorption and disposition
[39], which can be highly related to functional roles of transporters. Nonetheless, the
implication of transporter functions to cancer drug sensitivity has never been studied
systematically. Solute carriers (SLC) are the second largest group of membrane
transporters comprising over 400 genes, yet they are the most neglected family in
the human genome, judging by the number of publications for each member of all
protein families [8]. This thesis therefore aims to computationally identify putative
associations between cancer cellular expression profiles of transporters and cancer
drugs, as well as take a closer look to their endogenous roles in cancer tissues.
This thesis exploited the recent availability of the Genomics of Drug Sensitivity
(GDSC) portal [9] [23], the largest pharmacogenomic database in cell lines. The
data comprises gene expression from microarray experiments for over 15,000 genes,
with the clinically significant genetic informations i.e. mutation and copy number
variation, known as cancer functional events (CFEs). Drug sensitivity screening for
265 compounds in 1,001 cell lines were used to identify drug-gene associations.
The first part of the thesis focused on the landscape of transporter gene expression
profiles at tissue level. Transporters that are differentially expressed in particular
tissues have been identified using moderated t-test and a number of literature support
for known cases were found, and novel cases were listed. Furthermore, matrix
factorisation-based data integration techniques were used to integrate the shared
information among different genetic data, resulting in a joint latent variable matrix
that represents tissue identities by using transporter information. It was found that
the identity of breast, skin, and large intestine cell lines can be recapitulated using
transporter information, while most other tissues share similar transporter profiles.
This information can be useful for identifications of endogenous roles of transporters
in tumour progression in particular tissues. Further analyses of cell line - patient
agreements of transporter profiles, which is a proxy to clinical implications, are also
needed to be done.
Additional to the landscape of transporters, their effect on drug sensitivity is a
central goal of this thesis. Several methods have been employed to capture these
associations. Known cases such as SLC35F2 and YM155 appear as a top hit in all
methods, reflecting the reliability of association methods used. SLC6A12 and DMOG
is also another association pair identified in this study that appears consistently in all
methods. With different sensitivity level and limitations, the other association pairs
are found in not all methods, and those that can be captured by multiple methods
were listed as proposed candidates for experimental validation. Furthermore, the
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analyses recapitulate the known functions of ABCB1 as a multidrug resistance
transporter, while providing a novel insight on the effect of SLC35F2 as multidrug
sensitivity transporter.
However, the effect of one drug can be mediated via multiple transporters. The
effects can either be (1) cooperativity: two transporters are needed for a drug to
reach the target, or (2) redundancy: drugs can be mediated by one of the transporters
independently. This question cannot be addressed by the association identification
from the previous section, and therefore a first-order interaction learning method
based on linear model with hierarchical group-lasso were employed to identify the
transporter interactions. This is a novel analysis that can computationally suggest
the joint function of transporters in drug action and the most significant pairs were
listed for future experimental validation.
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A Appendix
A.1 TCGA tissue label abbreviations
Table A1: Tissue label abbreviation used in TCGA
Tissue Abbreviation
Acute Myeloid Leukemia LAML
Adrenocortical carcinoma ACC
Bladder Urothelial Carcinoma BLCA
Brain Lower Grade Glioma LGG
Breast invasive carcinoma BRCA
Cervical squamous cell carcinoma and endocervical adenocarcinoma CESC
Cholangiocarcinoma CHOL
Colon adenocarcinoma COAD
Esophageal carcinoma ESCA
FFPE Pilot Phase II FPPP
Glioblastoma multiforme GBM
Head and Neck squamous cell carcinoma HNSC
Kidney Chromophobe KICH
Kidney renal clear cell carcinoma KIRC
Kidney renal papillary cell carcinoma KIRP
Liver hepatocellular carcinoma LIHC
Lung adenocarcinoma LUAD
Lung squamous cell carcinoma LUSC
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma DLBC
Mesothelioma MESO
Ovarian serous cystadenocarcinoma OV
Pancreatic adenocarcinoma PAAD
Pheochromocytoma and Paraganglioma PCPG
Prostate adenocarcinoma PRAD
Rectum adenocarcinoma READ
Sarcoma SARC
Skin Cutaneous Melanoma SKCM
Stomach adenocarcinoma STAD
Testicular Germ Cell Tumors TGCT
Thymoma THYM
Thyroid carcinoma THCA
Uterine Carcinosarcoma UCS
Uterine Corpus Endometrial Carcinoma UCEC
Uveal Melanoma UVM
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A.2 Tissue-specific transporters
This table provide the list of significant tissue specificity of SLC and ABC transporters,
corresponding to Figure 8.
Solute Carriers (SLC)
gene tissue logFC Avexpr t P.Value
SLC52A1 HNSC 1.112 3.502 14.1840 9.8E-41
SLC31A2 HNSC 1.913 4.516 13.3448 1.1E-36
SLC2A9 HNSC 1.739 3.444 11.8705 5.8E-30
SLC47A2 HNSC 1.326 3.571 10.0933 1.4E-22
RHCG HNSC 0.718 3.232 10.0410 2.2E-22
SLC52A1 ESCA 1.025 3.502 11.5693 1.2E-28
SLC22A16 LAML 2.004 3.323 19.8926 2.4E-71
SLC39A3 LAML 1.054 3.895 12.6195 2.6E-33
SLC2A5 LAML 1.292 3.244 11.6203 7.2E-29
SLC22A15 LAML 1.248 3.322 11.4462 4.0E-28
SLC26A8 LAML 0.448 3.004 11.0963 1.2E-26
SLC6A16 DLBC 0.864 3.055 16.4065 4.3E-52
SLC2A5 DLBC 1.278 3.244 12.6351 2.2E-33
SLC35D2 DLBC -2.597 6.420 -9.9700 4.2E-22
SLC43A2 DLBC 0.385 3.376 9.7064 4.3E-21
SLC25A27 DLBC 1.269 3.661 9.6144 9.7E-21
RHAG LCML 3.398 3.263 12.9713 6.2E-35
SLC9A9 MM 1.182 3.212 11.8110 1.1E-29
SLC38A5 MM 3.264 3.956 10.1953 5.6E-23
SLC25A42 MM 0.768 3.453 9.7111 4.2E-21
SLC7A3 ALL 1.900 3.099 13.1035 1.5E-35
SLC25A42 ALL 0.685 3.453 9.9969 3.3E-22
SLC24A3 BRCA 2.452 3.289 15.1964 8.5E-46
SLC16A1 BRCA -1.713 8.157 -10.1900 5.9E-23
SLC5A1 COREAD 1.586 3.183 17.9526 1.9E-60
SLC6A20 COREAD 1.588 3.376 17.7170 3.7E-59
SLC12A2 COREAD 2.735 5.455 16.0636 2.8E-50
SLC26A3 COREAD 1.750 2.995 13.6787 2.8E-38
SLC44A4 COREAD 1.937 3.668 10.8807 9.6E-26
SLC52A3 COREAD 0.559 3.619 10.7259 4.1E-25
SLC9A2 COREAD 0.933 3.257 10.6948 5.6E-25
SLC39A5 COREAD 0.908 4.047 10.2919 2.3E-23
SLC22A9 LIHC 1.110 3.001 14.2895 3.0E-41
SLC47A1 LIHC 1.019 3.312 9.8115 1.7E-21
SLC4A4 KIRC 1.219 2.988 18.5752 6.6E-64
SLC17A3 KIRC 1.141 3.272 15.2455 4.8E-46
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SLC17A1 KIRC 0.860 3.107 12.9898 5.1E-35
SLC41A2 KIRC 1.622 3.948 12.8537 2.2E-34
SLC16A12 KIRC 1.650 2.965 10.1332 9.8E-23
SLC7A14 SCLC 0.982 3.150 13.6103 5.9E-38
SLC36A4 SCLC 2.083 6.056 12.9740 6.0E-35
SLC25A43 SCLC -1.407 4.652 -12.6076 2.9E-33
SLC17A6 SCLC 0.928 3.077 11.4429 4.2E-28
SLC35D3 SCLC 1.090 3.136 11.3002 1.7E-27
SLC10A3 SCLC -1.067 5.225 -10.1070 1.2E-22
SLC35F4 SCLC 0.721 3.082 9.8172 1.6E-21
SLC14A1 GBM 2.093 3.273 10.2755 2.7E-23
SLC6A2 NB 2.342 3.292 29.2843 3.3E-127
SLC10A4 NB 5.284 3.558 24.9132 6.8E-101
SLC4A8 NB 1.256 3.310 17.7105 4.0E-59
SLC26A10 NB 2.048 3.488 16.4052 4.4E-52
SLC18A1 NB 1.673 3.494 13.2522 3.0E-36
SLC8A3 NB 1.920 3.212 12.6501 1.9E-33
SLC6A15 NB 3.184 4.111 11.7866 1.4E-29
SLC29A4 NB 0.519 3.438 11.3125 1.5E-27
SLC8A1 NB 0.990 3.412 10.9208 6.6E-26
SLC45A2 SKCM 3.499 3.428 36.5639 2.3E-170
SLC24A5 SKCM 4.455 3.791 34.2009 1.5E-156
SLC5A4 SKCM 1.604 3.311 21.2039 6.4E-79
SLC16A6 SKCM 3.259 3.775 20.0066 5.3E-72
SLC23A2 SKCM 0.879 3.652 18.5261 1.2E-63
SLC38A1 SKCM -3.130 10.107 -16.4763 1.8E-52
SLC1A4 SKCM 2.078 4.820 15.7776 8.6E-49
SLC35F1 SKCM 1.291 3.411 14.2512 4.6E-41
SLC6A15 SKCM 2.567 4.111 12.6728 1.5E-33
SLC35B4 SKCM 1.591 5.646 12.4775 1.1E-32
SLC35B2 SKCM 1.020 6.439 12.2971 7.4E-32
SLC6A8 SKCM 1.791 6.578 11.5757 1.1E-28
SLC27A1 SKCM 0.303 3.236 11.5395 1.6E-28
SLC37A3 SKCM 0.737 4.182 10.7844 2.4E-25
SLC19A2 SKCM 1.435 5.141 10.6884 5.9E-25
SLC26A4 SKCM 0.776 2.996 10.6679 7.2E-25
SLC27A3 SKCM 0.909 3.642 9.9013 7.8E-22
SLC26A2 SKCM 1.894 6.528 9.7312 3.5E-21
SLC34A2 OV 2.094 3.154 13.9837 9.4E-40
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ATP-binding cassettes (ABC)
gene tissue logFC AveExpr t P.Value
ABCB10 LAML 1.429 7.494 10.9721 4.0E-26
ABCD2 MM 0.611 2.798 9.9638 4.5E-22
ABCC11 BRCA 0.689 3.151 14.5259 2.0E-42
CFTR COREAD 2.537 3.439 16.9268 7.2E-55
ABCA5 SCLC 1.209 3.542 13.2399 3.4E-36
TAP1 SCLC -1.925 7.456 -10.0271 2.5E-22
TAP1 NB -3.282 7.456 -12.4167 2.2E-32
ABCB5 SKCM 0.555 3.007 18.5492 9.3E-64
ABCB4 SKCM 1.226 3.305 12.4116 2.3E-32
ABCG5 SKCM 0.625 3.064 10.0183 2.7E-22
